Cargando…

Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland

BACKGROUND: Despite positive results from phase II and observational studies, Rituximab (RTX) is not currently approved for multiple sclerosis (MS) treatment and can only be used off-label. OBJECTIVE: To characterize MS patients treated with RTX and investigate its effectiveness and safety in a clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scotti, Barbara, Disanto, Giulio, Sacco, Rosaria, Guigli, Marilu’, Zecca, Chiara, Gobbi, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951582/ https://www.ncbi.nlm.nih.gov/pubmed/29758075 http://dx.doi.org/10.1371/journal.pone.0197415

Ejemplares similares

Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients
por: Zecca, Chiara, et al.
Publicado: (2019)

Influence of Disease Modifying Treatment, Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Vaccination on Coronavirus Disease 2019 Risk and Outcome in Multiple Sclerosis and Neuromyelitis Optica
por: Eisler, Jennifer Jessica, et al.
Publicado: (2023)

Increasing cancer risk over calendar year in people with multiple sclerosis: a case–control study
por: Zecca, Chiara, et al.
Publicado: (2020)

Contribution of sleep disturbances to fatigue in multiple sclerosis: a prospective study using clinical and polysomnographic parameters
por: Riccitelli, Gianna C., et al.
Publicado: (2021)

Recurrence and Prognostic Value of Asymptomatic Spinal Cord Lesions in Multiple Sclerosis
por: Ostini, Camilla, et al.
Publicado: (2021)

Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study
por: Zecca, Chiara, et al.
Publicado: (2017)

Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment
por: Caporro, Matteo, et al.
Publicado: (2014)

Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year
por: Disanto, Giulio, et al.
Publicado: (2022)

Fatigue, sleepiness and depression in multiple sclerosis: defining the overlaps for a better phenotyping
por: Sparasci, Davide, et al.
Publicado: (2022)

Migraine in Multiple Sclerosis Patients Affects Functional Connectivity of the Brain Circuitry Involved in Pain Processing
por: Pravatà, Emanuele, et al.
Publicado: (2021)

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
por: Disanto, Giulio, et al.
Publicado: (2017)

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
por: Salzer, Jonatan, et al.
Publicado: (2016)

Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study
por: Yamout, Bassem I., et al.
Publicado: (2018)

Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis
por: Chalkou, Konstantina, et al.
Publicado: (2021)

Safety of breast feeding during rituximab treatment in multiple sclerosis
por: Rød, Brit Ellen, et al.
Publicado: (2023)

Experiences of persons with multiple sclerosis with the Covid-19 vaccination: A cross-sectional study of the Swiss Multiple Sclerosis Registry
por: Stanikić, Mina, et al.
Publicado: (2023)

Serious safety events in rituximab‐treated multiple sclerosis and related disorders
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Evaluation of safety of rituximab in patients with multiple sclerosis: A retrograde study
por: Majdinasab, Nastaran, et al.
Publicado: (2020)

Efficacy and safety of rituximab in patients with multiple sclerosis: An observational study at a tertiary center in Makkah, Saudi Arabia
por: Almatrafi, Yassir M., et al.
Publicado: (2022)

Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland
por: Kaufmann, Marco, et al.
Publicado: (2018)

Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis
por: Zrzavy, Tobias, et al.
Publicado: (2021)

SwissTecLive: effectiveness and safety of dimethyl fumarate in the treatment of RRMS in the Swiss clinical practice setting
por: Zecca, Chiara, et al.
Publicado: (2020)

Multiple sclerosis, rituximab, and COVID‐19
por: Langer‐Gould, Annette, et al.
Publicado: (2021)

Improvement of interferon-beta related skin reactions after diluent halving: first experience of five patients
por: Zecca, Chiara, et al.
Publicado: (2012)

Corrigendum to “Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis”
Publicado: (2021)

Rituximab for the treatment of multiple sclerosis: a review
por: Chisari, Clara Grazia, et al.
Publicado: (2021)

The Refinement of Genetic Predictors of Multiple Sclerosis
por: Disanto, Giulio, et al.
Publicado: (2014)

Estimating the proportion of variation in susceptibility to multiple sclerosis captured by common SNPs
por: Watson, Corey T., et al.
Publicado: (2012)

Sleep-Related Breathing Disorders in Multiple Sclerosis: Prevalence, Features and Associated Factors
por: Sparasci, Davide, et al.
Publicado: (2022)

Smoking and Multiple Sclerosis: An Updated Meta-Analysis
por: Handel, Adam E., et al.
Publicado: (2011)

Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study
por: Torgauten, Hilde Marie, et al.
Publicado: (2021)

Life-threatening asthma attack during prolonged fingolimod treatment: case report
por: Zecca, Chiara, et al.
Publicado: (2014)

Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection—a case report
por: Zecca, Chiara, et al.
Publicado: (2015)

Rituximab in early systemic sclerosis
por: Boonstra, Maaike, et al.
Publicado: (2017)

Rituximab as Rescue Therapy for Aggressive Pediatric Multiple Sclerosis
por: Vartzelis, George, et al.
Publicado: (2019)

Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab
por: Perriguey, Marine, et al.
Publicado: (2021)

Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?
por: Brancati, Serena, et al.
Publicado: (2021)

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options
por: Disanto, Giulio, et al.
Publicado: (2016)

Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS)
por: Achtnichts, Lutz, et al.
Publicado: (2023)

The Effect of Depression on Health-Related Quality of Life Is Mediated by Fatigue in Persons with Multiple Sclerosis
por: Rodgers, Stephanie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tu78p4ir1cfriv87p9s9nvqlht